Ovarian cancer screening: a look at the evidence.

In 2005, more than 22,000 American women were diagnosed with ovarian cancer and 16,000 women died from the disease. The five-year relative survival rate for stage III and IV disease is 31%, and the five-year relative survival rate for stage I is 95%. Early diagnosis should lower the fatality rate.

Screening for disease: making evidence-based choices.

Screening for illness should be an evidence-based activity. Screening tests are useful only if they reduce mortality or morbidity. Therefore, healthcare professionals must know how to evaluate research about screening tests to be sure that, in fact, the tests actually accomplish their goals.

From mechanisms to management: translating the neuropathic pain consensus recommendations into clinical practice.

Chronic neuropathic pain poses a treatment challenge, and is associated with significant psychologic distress, physical disability, and impaired functioning, which impact the activities of daily living. Efforts to provide relief are often inadequate and/or require polypharmacy. This has spurred interest among researchers and clinicians alike to develop early, intensive treatments that target the molecular and cellular mechanisms involved in pain transduction, transmission, and modulation, or ideally, that prevent neuropathic pain from occurring in the first place.

Recent advances in clinical use of opioids.

Opioid therapy for pain is the subject of numerous randomized clinical trials. Opioids are being developed for delivery by a wide variety of mechanisms. New opioids are becoming available for clinical use.